Allison Dorval - 14 Feb 2024 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Financial Officer
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Allison Dorval
Issuer symbol
VERV
Transactions as of
14 Feb 2024
Transactions value $
$0
Form type
4
Filing time
16 Feb 2024, 16:30:12 UTC
Previous filing
01 Dec 2023
Next filing
07 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +180,000 $0 180,000 14 Feb 2024 Common Stock 180,000 $12.75 Direct F1
transaction VERV Restricted Stock Units Award $0 +45,000 $0 45,000 14 Feb 2024 Common Stock 45,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028.